Lexicon Pharmaceuticals (NASDAQ:LXRX) Trading Up 5%

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) shares were up 5% during mid-day trading on Friday . The company traded as high as $5.28 and last traded at $5.28. Approximately 4,397 shares changed hands during trading, a decline of 100% from the average daily volume of 2,264,275 shares. The stock had previously closed at $5.03.

A number of equities analysts have recently issued reports on LXRX shares. Zacks Investment Research downgraded Lexicon Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Wednesday, July 28th. Citigroup lifted their target price on Lexicon Pharmaceuticals from $13.00 to $20.00 and gave the stock a “buy” rating in a report on Monday, August 30th. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and three have issued a buy rating to the company’s stock. According to data from MarketBeat, Lexicon Pharmaceuticals currently has an average rating of “Hold” and a consensus target price of $10.29.

The firm has a market capitalization of $713.70 million, a P/E ratio of 12.67 and a beta of 1.46. The stock has a fifty day simple moving average of $4.08 and a two-hundred day simple moving average of $4.67.

Lexicon Pharmaceuticals (NASDAQ:LXRX) last issued its earnings results on Friday, July 30th. The biopharmaceutical company reported ($0.13) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.16) by $0.03. Lexicon Pharmaceuticals had a return on equity of 27.59% and a net margin of 536.83%. The business had revenue of $0.23 million during the quarter, compared to the consensus estimate of $0.03 million. As a group, analysts forecast that Lexicon Pharmaceuticals, Inc. will post -0.58 earnings per share for the current fiscal year.

Institutional investors have recently made changes to their positions in the business. Royal Bank of Canada grew its stake in Lexicon Pharmaceuticals by 283.8% in the first quarter. Royal Bank of Canada now owns 4,652 shares of the biopharmaceutical company’s stock valued at $27,000 after acquiring an additional 3,440 shares during the period. Amalgamated Bank acquired a new stake in Lexicon Pharmaceuticals in the second quarter valued at approximately $50,000. HighTower Advisors LLC acquired a new stake in Lexicon Pharmaceuticals in the first quarter valued at approximately $64,000. Credit Suisse AG acquired a new stake in Lexicon Pharmaceuticals in the first quarter valued at approximately $65,000. Finally, Citigroup Inc. grew its stake in Lexicon Pharmaceuticals by 234.1% in the second quarter. Citigroup Inc. now owns 11,595 shares of the biopharmaceutical company’s stock valued at $53,000 after acquiring an additional 8,124 shares during the period. 84.85% of the stock is owned by hedge funds and other institutional investors.

Lexicon Pharmaceuticals Company Profile (NASDAQ:LXRX)

Lexicon Pharmaceuticals, Inc engages in the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. Its drug candidates include: LX9211, an orally-delivered small molecule drug candidate, as a treatment for neuropathic pain; and sotagliflozin, a treatment for heart failure and type 1 diabetes.

See Also: What is a dead cat bounce?

Receive News & Ratings for Lexicon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lexicon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.